FUKOKU MUTUAL LIFE INSURANCE Co maintained its stake in Boston Scientific Corporation (NYSE:BSX) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,744 shares of the medical equipment provider’s stock at the close of the second quarter. FUKOKU MUTUAL LIFE INSURANCE Co’s holdings in Boston Scientific Corporation were worth $242,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Swiss National Bank boosted its holdings in Boston Scientific Corporation by 2.9% in the second quarter. Swiss National Bank now owns 5,584,930 shares of the medical equipment provider’s stock worth $154,814,000 after acquiring an additional 156,800 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Boston Scientific Corporation by 10.5% in the second quarter. Wells Fargo & Company MN now owns 9,157,768 shares of the medical equipment provider’s stock worth $253,854,000 after acquiring an additional 867,983 shares during the last quarter. Koch Industries Inc. purchased a new stake in shares of Boston Scientific Corporation in the first quarter worth $307,000. Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Boston Scientific Corporation by 35,016.2% in the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 3,042,464 shares of the medical equipment provider’s stock worth $84,337,000 after acquiring an additional 3,033,800 shares during the last quarter. Finally, Bellevue Group AG grew its stake in shares of Boston Scientific Corporation by 4.0% in the first quarter. Bellevue Group AG now owns 572,000 shares of the medical equipment provider’s stock worth $14,226,000 after acquiring an additional 22,000 shares during the last quarter. Institutional investors and hedge funds own 90.44% of the company’s stock.

BSX has been the subject of several analyst reports. Zacks Investment Research downgraded Boston Scientific Corporation from a “buy” rating to a “hold” rating in a report on Thursday, June 29th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $31.00 price target (up previously from $27.00) on shares of Boston Scientific Corporation in a research note on Wednesday, June 28th. Royal Bank Of Canada reiterated a “buy” rating and issued a $31.00 price target on shares of Boston Scientific Corporation in a research note on Wednesday, July 12th. Wells Fargo & Company reissued an “outperform” rating and set a $31.00 price objective (up from $29.50) on shares of Boston Scientific Corporation in a research report on Friday, June 16th. Finally, Needham & Company LLC increased their price objective on shares of Boston Scientific Corporation from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 22nd. One research analyst has rated the stock with a sell rating, five have given a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $30.12.

In other news, CFO Daniel J. Brennan sold 92,158 shares of the firm’s stock in a transaction dated Tuesday, July 11th. The stock was sold at an average price of $27.48, for a total value of $2,532,501.84. Following the completion of the transaction, the chief financial officer now directly owns 235,421 shares in the company, valued at $6,469,369.08. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Timothy A. Pratt sold 11,061 shares of the firm’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $29.24, for a total value of $323,423.64. Following the completion of the transaction, the executive vice president now owns 174,681 shares of the company’s stock, valued at $5,107,672.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 276,318 shares of company stock valued at $7,567,967. 0.74% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: “FUKOKU MUTUAL LIFE INSURANCE Co Continues to Hold Holdings in Boston Scientific Corporation (BSX)” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/03/fukoku-mutual-life-insurance-co-continues-to-hold-holdings-in-boston-scientific-corporation-bsx.html.

Boston Scientific Corporation (NYSE BSX) traded down 1.66% during midday trading on Tuesday, hitting $28.98. The company’s stock had a trading volume of 1,285,228 shares. The company’s 50-day moving average is $27.99 and its 200 day moving average is $26.89. The company has a market cap of $39.76 billion, a price-to-earnings ratio of 51.84 and a beta of 1.09. Boston Scientific Corporation has a one year low of $19.67 and a one year high of $29.50.

Boston Scientific Corporation (NYSE:BSX) last released its earnings results on Thursday, July 27th. The medical equipment provider reported $0.32 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.01. The firm had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific Corporation had a return on equity of 23.62% and a net margin of 9.04%. The firm’s revenue was up 6.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.27 EPS. On average, analysts predict that Boston Scientific Corporation will post $1.26 EPS for the current year.

Boston Scientific Corporation Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific Corporation (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.